239 related articles for article (PubMed ID: 31655825)
21. Secreted aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) is a promising predictor for the severity of acute AQP4-IgG positive neuromyelitis optica spectrum disorder.
Yuan C; Liu X; Cai S; Zhang L; Guo R; Jia Z; Sun Y; Li B
Mult Scler Relat Disord; 2023 Feb; 70():104504. PubMed ID: 36623394
[TBL] [Abstract][Full Text] [Related]
22. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
[TBL] [Abstract][Full Text] [Related]
23. Discrepancy in clinical and laboratory profiles of NMOSD patients between AQP4 antibody positive and negative: can NMOSD be diagnosed without AQP4 antibody?
Chu F; Shi M; Liu C; Zhu J
Clin Exp Immunol; 2023 Oct; 213(3):363-370. PubMed ID: 37161978
[TBL] [Abstract][Full Text] [Related]
24. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
[TBL] [Abstract][Full Text] [Related]
25. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
[TBL] [Abstract][Full Text] [Related]
26. Impact of blood-brain barrier disruption on newly diagnosed neuromyelitis optica spectrum disorder symptoms and prognosis.
Liang S; Qin Q; Tang Y; Liao W; Yang Y; He J; Li L
Ann Palliat Med; 2020 Mar; 9(2):324-330. PubMed ID: 32268769
[TBL] [Abstract][Full Text] [Related]
27. Serum Homocysteine Level Is a Predictor of Relapse and Prognosis in Patients With First-Attack Neuromyelitis Optica Spectrum Disorders.
Zhang J; Li Y; Zhou Y; Zhao Y; Xie H; Duan R; Yao Y; Gong Z; Teng J; Jia Y
Front Neurol; 2021; 12():667651. PubMed ID: 34122309
[No Abstract] [Full Text] [Related]
28. Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder.
Sun H; Cui S; Gao F; You Q; Li Y; Wang J; Zhang X
J Neurol Sci; 2018 Jan; 384():91-95. PubMed ID: 29249386
[TBL] [Abstract][Full Text] [Related]
29. Spinal cord involvement by atrophy and associations with disability are different between multiple sclerosis and neuromyelitis optica spectrum disorder.
Nakamura Y; Liu Z; Fukumoto S; Shinoda K; Sakoda A; Matsushita T; Hayashida S; Isobe N; Watanabe M; Hiwatashi A; Yamasaki R; Kira JI
Eur J Neurol; 2020 Jan; 27(1):92-99. PubMed ID: 31304648
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.
Sato DK; Callegaro D; de Haidar Jorge FM; Nakashima I; Nishiyama S; Takahashi T; Simm RF; Apostolos-Pereira SL; Misu T; Steinman L; Aoki M; Fujihara K
Ann Neurol; 2014 Aug; 76(2):305-9. PubMed ID: 24977390
[TBL] [Abstract][Full Text] [Related]
31. Serum anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder presenting as acute eosinophilic encephalomyelitis.
Muroishi T; Sakai K; Yanase D; Ikeda Y; Machiya T; Kato-Motozaki Y; Samuraki M; Yamada M
J Clin Neurosci; 2018 Feb; 48():93-94. PubMed ID: 29137920
[TBL] [Abstract][Full Text] [Related]
32. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
[TBL] [Abstract][Full Text] [Related]
33. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders.
Tang J; Zeng X; Yang J; Zhang L; Li H; Chen R; Tang S; Luo Y; Qin X; Feng J
Front Immunol; 2022; 13():766099. PubMed ID: 35185873
[TBL] [Abstract][Full Text] [Related]
34. Urinalysis in patients with neuromyelitis optica spectrum disorder.
Chen ZG; Huang J; Fan R; Weng RH; Shinohara RT; Landis JR; Chen Y; Jiang Y
Eur J Neurol; 2020 Apr; 27(4):619-625. PubMed ID: 31729806
[TBL] [Abstract][Full Text] [Related]
35. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
36. Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders.
Dujmovic I; Mader S; Schanda K; Deisenhammer F; Stojsavljevic N; Kostic J; Berger T; Drulovic J; Reindl M
J Neuroimmunol; 2011 May; 234(1-2):124-30. PubMed ID: 21316112
[TBL] [Abstract][Full Text] [Related]
37. Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders.
Akaishi T; Takahashi T; Himori N; Fujihara K; Misu T; Abe M; Ishii T; Nakazawa T; Aoki M; Nakashima I
J Neuroimmunol; 2020 Mar; 340():577168. PubMed ID: 31986374
[TBL] [Abstract][Full Text] [Related]
38. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
[TBL] [Abstract][Full Text] [Related]
39. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
Tao S; Zhang Y; Ye H; Guo D
Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
[TBL] [Abstract][Full Text] [Related]
40. Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders.
Zhang DQ; Jia K; Wang R; Li T; Zhao N; Yang LN; Yang L
J Neuroimmunol; 2016 Apr; 293():100-104. PubMed ID: 27049569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
